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SRS 19-6 MuLV is a murine retrovirus originally isolated in mainland China. A noteworthy feature of this virus (referred to as SRS MuLV
here) induces tumors of multiple hematopoietic lineages, including myeloid, erythroid, T-lymphoid and B-lymphoid. To identify the determinants
of disease specificity, chimeras between SRS and Moloney MuLV (M-MuLV) were generated by molecular cloning, and the pathogenic properties
of the chimeras were investigated. The results indicated that, while the M-MuLV LTR can confer lymphoid specificity to SRS MuLV, the SRS
LTR by itself was not sufficient to confer multiple lineage tumorigenesis to M-MuLV; additional sequences in gag or pol were also required. Thus,
a secondary determinant for myeloid/erythroid leukemia in SRS MuLV is located in gag–pol. In these chimeras, an independent determinant for T-
lymphoma was found in M-MuLV gag–pol. It was also interesting that insertion of M-MuLV env into SRS MuLV decreased the rate of
leukemogenicity, while insertion of SRS env into M-MuLV (SEM) accelerated leukemogenesis. The enhanced pathogenicity of SEM was found to
correlate with earlier formation of MCF recombinants. The basis for the accelerated MCF recombinant formation was investigated. The
endogenous polytropic MuLV env sequences contributing to several SEM MCF recombinants were identified, and the cross-over points were
identified. While no obvious differences in the relative homologies between SRS MuLV env and polytropic env vs. M-MuLV and polytropic envs
suggested a reason for the more rapid MCF recombinant formation, an overlapping but different set of polytropic env proviruses were found to
participate in MCF formation for M-MuLV vs. SEM. Thus, the mechanisms for MCF formation appear to differ for M-MuLV and SEM.
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Murine leukemia viruses are prototypic replication-compe-
tent oncogenic retroviruses. These viruses have been exten-
sively studied with regard to the mechanism(s) by which they
induce tumors (Fan, 1997). They lack oncogenes, and an
important mechanism in leukemogenesis is insertional activa-
tion of proto-oncogenes (Rosenberg and Jolicoeur, 1997). In
this process, an MuLV provirus is integrated into a host
chromosome in the vicinity of a cellular proto-oncogene on a
random basis. This insertion leads to over-expression of the⁎ Corresponding author. Fax: +1 949 824 4023.
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doi:10.1016/j.virol.2006.03.010cellular proto-oncogene either through read-through transcrip-
tion (promoter insertion) or by activation of the proto-
oncogene's promoter by the enhancers in the MuLV long
terminal repeat (LTR) (enhancer activation). Different MuLVs
typically activate a small number of proto-oncogenes during
oncogenesis; depending on the MuLV, a different set of proto-
oncogenes may be activated (Rosenberg and Jolicoeur, 1997).
Retrovirus-induced tumors have been employed for gene
discovery of new proto-oncogenes (Suzuki et al., 2002; Cuypers
et al., 1984; Nusse and Varmus, 1982).
One consequence of the proto-oncogene activation mecha-
nism for MuLV leukemogenesis is that the tissue specificity of
the disease is heavily influenced by the U3 enhancer sequences
in the viral LTR (Fan, 1997). Since these enhancer sequences
are key in insertional activation of proto-oncogenes (either
through direct activation of the proto-oncogene promoter, or
through activation of the viral LTR promoter in the promoter
Fig. 1. SRS-M-MuLV chimeras. The genetic organizations of the chimeras used
in this study are shown in proviral DNA form (after reverse transcription). The
boxes at either end represent the LTRs, and the two parental viruses are shown at
the top. The locations of common HindIII (H) and NheI (N) sites used for
generation of the chimeras are indicated as well. The enhancer sequences in Scl-
15 were derived from an SRS MuLV-induced T-lymphoid tumor (Granger et al.,
1999).
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MuLV can be altered by exchanging the enhancer sequences. In
classic experiments, substitution of the enhancer sequences
from Friend MuLV that induces erytholeukemia into the LTR of
Moloney murine leukemia virus (M-MuLV) that induces T-
lymphoma yielded a chimeric virus that induces erythroleuke-
mia (Chatis et al., 1984; Li et al., 1987).
While insertional activation of proto-oncogenes is an
essential part of MuLV leukemogenesis, it is also clear that
this alone is not sufficient to cause a neoplasm. Like most
carcinogenic processes, MuLV leukemogenesis is multi-step.
We have extensively studied pre-leukemic events in M-MuLV-
infected mice (Fan, 1997). These events include defects in bone
marrow stroma (Li and Fan, 1990), accelerated thymic atrophy
(Bonzon and Fan, 2000), enhanced thymocyte apoptosis
(Bonzon and Fan, 2000) and formation of MCF (mink cell
focus-inducing) recombinants (Brightman et al., 1991). MCFs
arise in vivo from recombination in the env gene between the
infecting MuLV and an endogenous MuLV-related (polytropic)
provirus; they infect cells via a different receptor than the
original (ecotropic) MuLV (Hartley et al., 1977). MCFs have
been shown to be important for efficient disease formation
(Hartley et al., 1977), and they may play roles early and/or late
during leukemogenesis (Brightman et al., 1991; Hartley et al.,
1977). Virus-driven events (e.g. additional proto-oncogene
activations) also occur during tumor progression and metastasis
(Bear et al., 1989; Patriotis et al., 1993).
SRS 19-6MuLVis a component of the TSZ complex ofMuLVs
that was originally isolated in mainland China (Bundy et al., 1995).
This virus has been molecularly cloned, and it was found to induce
an unusually broad range of different leukemias inNIHSwissmice,
including myeloid and erythroid leukemias and B- and T-
lymphomas (Bundy et al., 1995). Such a broad spectrum of
diseases is unusual forMuLVs that typically induce a single type of
leukemia under a given experimental condition (e.g. M-MuLVand
T-lymphoma in NIH Swiss mice). We previously tested if the SRS
19-6 LTR contains determinants of the broad disease specificity by
generating a chimeric virus in which the SRS enhancers were
substituted into the M-MuLV LTR (ΔMo+SRS M-MuLV)
(Granger et al., 1999). Somewhat surprisingly, this virus induced
T-lymphoma rather than leukemias of multiple lineages. To further
investigate disease specificity determinants, a systematic series of
reciprocal chimeras between SRS 19-6 and M-MuLV were
generated and tested in the studies described in this report. The
studies yielded some unexpected results, both in terms of the
regions containing determinants of disease specificity and in the rate
of disease formation.
Results
Generation of chimeras between SRS- and M-MuLV
To investigate the regions of the SRS- and M-MuLV
genomes that contain determinants for disease specificity, a
series of chimeras between the two viruses was generated. As
described in Materials and methods, recombinants between
proviral plasmids for SRS 19-6 MuLV and M-MuLV weregenerated by molecular cloning. Exchanges between different
regions were facilitated by shared restriction endonuclease sites:
aHindIII site at the 3′ end of the pol gene and an NheI site in the
5′ end of the LTR. Infectious viruses were obtained by
transfection of the plasmids into NIH-3T3 fibroblasts, and
Fig. 1 shows resulting chimeric viruses in proviral form. This
takes into account the fact that, during reverse transcription, U3
sequences from the downstream LTR encode the U3 sequences
in both upstream and downstream LTRs in the resulting
proviruses. Likewise, U5 sequences from the upstream LTR
encode the U5 sequences in both LTRs. For instance, the
recombinant plasmid giving rise to SLTR was an M-MuLV
proviral plasmid containing SRS LTR sequences in only the
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plasmid form of 5S3M was a recombinant plasmid containing
SRS proviral sequences to the 5′ side of the HindIII site and M-
MuLV proviral sequences downstream.
Inoculation of chimeric viruses into mice
The chimeric viruses were inoculated into neonatal NIH
Swiss mice, and the animals were observed for disease as
described previously (Bundy et al., 1995). Moribund animals
were sacrificed, subjected to gross pathological analysis, and
cellular DNAs from enlarged organs (thymus, spleen and/or
lymph nodes depending on the animal) were extracted. Blood
smears and tissue touch prints were also prepared for
histopathology. The time courses to disease for the chimeras
are shown in Fig. 2. Diagnoses of the tumor type(s) arising in
the infected animals are summarized in Table 1. We previously
characterized tumors induced by SRS-MuLV, and a feature
was that many of the animals show multiple tumors of
different hematopoietic lineages (Bundy et al., 1995). InFig. 2. Leukemogenicity of the chimeras. Kaplan–Meier survival curves are
shown for neonatal mice inoculated IP with each of the chimeras. Mice were
sacrificed when disease first became evident. (A) SRS MuLV-based chimeras
containing different regions of M-MuLV. (B) M-MuLV-based chimeras
containing different regions of SRS MuLV.contrast, M-MuLV induces exclusively T-lymphomas in these
mice (Brightman et al., 1988). A reliable indicator of myeloid
or erythroid tumors in SRS-MuLV-inoculated mice was found
to be low hematocrits (<31% for males, <29% for females)
(Bundy et al., 1995). In contrast, animals with lymphoid
tumors show normal hematocrits. Therefore, in this study,
animals were classified as having myeloid or erythroid
leukemia (M/E) if they had low hematocrits. To distinguish
between B- and T-lymphomas, Southern blot hybridization for
rearrangements in T-cell receptor (TCR) and immunoglobulin
(Ig) genes was employed (Brightman et al., 1988); animals
with tumors showing TCR-beta gene rearrangements were
classified as having T-lymphoid tumors, and animals with
tumors showing Ig kappa light chain (IgK) rearrangements or
animals with tumors showing Ig mu heavy chain (IgH) but no
TCR-beta rearrangements were classified as having B-
lymphoid tumors. As shown, many of the animals contained
tumors of both myeloid and lymphoid lineages. For instance,
SRS MuLV induced at least six combinations of tumors in 20
mice examined (exclusively T-lymphoma, T-lymphoma plus
B-lymphoma, null cell lymphoma, T-lymphoma plus myeloid/
erythroid leukemia, T-lymphoma plus B-lymphoma plus
myeloid/erythroid leukemia and exclusively myeloid/erythroid
leukemia). Since M-MuLV induces exclusively T-lymphoma
while SRS MuLV induces a substantial percentage of myeloid/
erythroid disease, the percentage of animals showing myeloid/
erythroid leukemia (either exclusively or in combination with a
lymphoma) is also shown in the table.
We also examined a subset of the tumors by histopathology of
blood smears or touch prints, where the hematocritswere borderline
normal, as shown in Table 2. As shown, there was excellent
agreement between the diagnoses based on gene rearrangements
and hematocrits (“Diagnosis”) and histopathology. The results of
these studies are described in the following sections.
Determinants for disease specificity
The primary goal of these studies was to identify regions of the
SRS genome that are responsible for the induction of tumors of
multiple lineages. For many otherMuLVs, the primary determinant
of disease specificity has been shown to be the U3 enhancer region
in the LTR. Somewhat surprisingly, the SRS enhancers by
themselveswere not extremely potent in altering disease specificity.
Substitution of the SRS LTR into the M-MuLV genome (SLTR)
yielded a virus that still induced predominantly T-lymphomas (13/
20 animals exclusively T-lymphoma; 19/20 animals with T-
lymphoma), while only 20% showed myeloid/erythroid leukemia.
This suggested that another region of the M-MuLV genome may
also contain a T-lymphoid determinant. Indeed, substitution of both
the SRS LTR and gag–pol region into M-MuLV (MES)
substantially reduced the frequency of T-lymphoma (1/13) and
increased the frequency of myeloid/erythroid disease (77%).
Moreover, insertion of the M-MuLV gag–pol region by itself into
SRS MuLV (5M3S) yielded a virus that induced a majority of T-
lymphomas (9/13 exclusively T-lymphoma; 100% T-lymphoma),
with reduced frequencies ofmyeloid/erythroid leukemias compared
to SRS-MuLV (15% vs. 52%).
Table 1
Tumors induced by chimeric viruses
Virus Latency a Tumor types b % M/E c % Td
M-MuLV 110 T (100%) 0* 100
SRS 19-6 MuLV 150 3/21 T, 3/21 T + B, 3/21 Null Cell lymphoma, 5/21 T + M/E, 1/21 T + B + M/E, 5/21 M/E 52 57
SLTR 125 13/20 T, 3/20 T + B, 3/20 T + M/E, 1/20 M/E 20 95
5M3S 130 9/13T, 2/13 T + B, 2/13 T + M/E 15.4 100
MES 170 1/13 T, 2/13 B, 3/13 T + B + M/E, 5/13 B + M/E, 2/13 M/E 77 31
MLTR 100 6/8 T, 2/8 B 0 75
5S3M 115 11/14 T, 2/14 T + B, 1/14 T + M/E 7.1 100
SEM 85 2/15 T, 12/15 T + B, 1/15 M/E 6.7 93
Scl-15 80 12/14 T, 1/14 T + M/E, 1/14 T + B + M/E 14.3 100
a Neonatal NIH Swiss mice were inoculated with each virus. The days post-inoculation when 50% of the animals showed signs of disease are indicated.
b Diagnosis of tumor type(s) in the animals was on the basis of gene arrangements for TCR-beta, Ig mu heavy chain and Ig kappa light chain genes and on
hematocrits and organ enlargements as described in Materials and methods. T, T-lymphoma; B, B-lymphoma; M/E, myeloid and/or erythroid leukemia. Many animals
showed evidence for more than one kind of tumor; the number with each tumor type as a fraction of the total number of animals examined is shown. Numerous
previous experiments have shown that M-MuLV induces exclusively T-lymphoma in these mice after IP inoculation.
c The percentage of animals with myeloid and/or erythroid leukemia, as judged by low hematocrits, is indicated. This includes animals that also showed other kinds
of leukemias (B- or T-lymphoid).
d The percentage of animals with T-lymphoid leukemia, as judged by TCR-beta rearrangements. This includes animals that also showed other kinds of leukemias
(B-lymphoid or myeloid and/or erythroid leukemia).
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lymphomas in these chimeras. Substitution of the M-MuLV
enhancer sequences into the SRS MuLV genome (MLTR)
resulted in a chimera that induced exclusively lymphomas (75%
T-lymphoma). The other two chimeras that contained the M-
MuLV LTR enhancers also induced predominantly lymphoma
(5S3M and SEM). It was interesting that SEM that contains only
the env sequences of SRSMuLV inserted into M-MuLV induced
predominantly mixed B- and T-lymphomas, in comparison to the
pure T-lymphomas induced by wild-type M-MuLV.
Determinants for the rate of disease appearance
The parental SRS and M-MuLVs differ in the rate of disease
appearance, with a mean latency of 150 and 110 days,
respectively. In general, those chimeras that contained the M-
MuLV LTR enhancers (MLTR, 5S3M, SEM) induced disease
more rapidly than those driven by the SRS enhancers (SLTR,Table 2
Histopathology of selected tumors
Animal Virus Hct a
(%)
Organ enlargement Gene rear
Thymus Nodes Spleen TCR
588.5-3F 5S3M 29 – IN,MN +++ R e
543-8M MES3 29 – IN + G
541-6M MES3 12 – – +++ G
593.4-13F Scl-15 23 E All +++ R
582.6-3F SLTR 13 – All +++ G
583.7-2F SLTR 26 E All +++ R
a Hematocrits.
b Diagnosis of tumor type(s) present based on hematocrits and gene rearrangemen
c Histopathological classification of the tumors based on microscopic observation
d Overall diagnosis combining histopathology and molecular diagnoses. This allow
analysis of nodal tumor tissue and brain (Br) was carried out.
e R, gene shows rearrangement by Southern blot hybridization of tumor DNAwith
T-cell receptor beta gene; IgH, immunoglobulin Mu heavy chain gene; IgK; immun5M3S, MES), which would be consistent with the M-MuLV
enhancers being more active (particularly in lymphoid cells)
than the SRS MuLVenhancers. In addition, the recombinants in
which the env genes were substituted into the opposite virus
showed the most dramatic effects. MES showed a noticeably
longer latency than the parental SRS MuLV, indicating that the
M-MuLVenvelope in the context of SRS MuLV LTR and other
coding sequences reduced the pathogenicity of the virus. In
contrast, SEM induced tumors with substantially shorter latency
than the parental M-MuLV (85 vs. 110 days). Thus, the SRS env
gene in the context of M-MuLV causes higher leukemogenicity
than the parental M-MuLV env gene.
SEM induces accelerated formation of MCF recombinants
The enhanced leukemogenicity of the SEM recombinant was
intriguing, and additional experiments were carried out to
investigate a possible mechanism. One hypothesis was thatrangements Diagnosis b Histopathology c Overall
diagnosis d
IgH IgK
R R T + B ± M/E LL (T or B) T + B
R G (Br) R R (Br) B + M/E LL (T or B) + M B + M
R (G) B + M/E B + M B + M
G G T + M/E T + E T + E
G G M/E E E
R G T + M/E T + E T + E
ts as tabulated in Table 1.
of stained blood smears or tissue touch prints.
ed distinguishing between myeloid and erythroid tumors. For animal 543-8M,
the appropriate gene probe; G, gene in the tumor shows no rearrangement. TCR,
oglobulin kappa light chain gene.
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recombinants are frequently observed in vivo after infection by
various MuLVs. They represent recombination between the
infecting (exogenous) MuLV and related endogenous MuLV-
related proviruses of the polytropic or modified polytropic class
(Frankel et al., 1989; Stoye et al., 1991). Moreover, a substantial
body of evidence has associated the temporal appearance of
MCF recombinants in vivo with development of tumors
(Hartley et al., 1977). We previously studied the time course
of appearance of MCF recombinants in NIH Swiss mice
infected neonatally with M-MuLV (Lander et al., 1999), and
similar experiments were carried out on mice infected with
SEM as shown in Fig. 3. Infected animals were sacrificed at
different times post-inoculation, cells from hematopoietic
organs were harvested (bone marrow, spleen and thymus),
and the numbers of cells producing MCF recombinants were
assessed by infectious center assays using focal immunofluo-
rescence and a monoclonal antibody specific for MCFs (MAb
514 (Chesebro et al., 1981; Cloyd and Evans, 1987)). It was
noteworthy that SEM-infected mice showed development of
MCF recombinants significantly more rapidly than M-MuLV-
infected animals. In particular, at very early times (e.g. 15 days),
MCF recombinants could be readily detected in most SEM-
infected animals, while they were virtually undetectable in M-
MuLV-infected mice (Figs. 3A–C). The more rapid appearance
of MCFs in SEM-infected mice was not simply a reflection of
more rapid establishment of infection since the rates at which
the input ecotropic SEM and M-MuLV established infectionFig. 3. MCF formation in SEM-infected animals. SEM- or M-MuLV-infected mice
thymus by infectious center assays (upper panels). Different numbers of cells from eac
MCF-infected cells were detected by focal immunofluorescence with the MCF-speci
assayed is shown with the value from each animal plotted. Multiple M-MuLV-infected
18 days. At day 21, 2 out of 3 M-MuLV-infected animals showed noMCFs in bone ma
the levels of SEM or M-MuLV infection were measured in the same organs (lower
extracellular Gag determinants for both viruses.were similar, as measured by focal immunofluorescence assay
with MAb 548 (Chesebro et al., 1981) (Figs. 3D–F). In
particular, equivalent levels of infection for the two input
viruses were observed at 15 days, while there was a dramatic
difference in MCF recombinants. These results indicated that
substitution of the SRS MuLV env gene into M-MuLV resulted
in more rapid development of MCF recombinants in vivo and
that this was correlated with more rapid disease onset.
One possible explanation for the more rapid appearance of
MCF recombinants in SEM-infected animals might be that the
SRS env sequences had higher homology with endogenous
polytropic env sequences than M-MuLV env sequences. The
likely mechanism for generation of MCF recombinants is
dimerization and co-packaging of an endogenous polytropic
MuLV RNA along with the exogenous MuLV RNA in a
heterozygous virus particle followed by infection into a second
cell where template switching between the env sequences
occurs during reverse transcription (Stoye et al., 1991;
Telesnitsky and Goff, 1997). Thus, higher frequencies of
recombination would be expected to occur between env
sequences with higher homology. Fig. 4 shows sequence
alignments between the env genes of SRS MuLV, M-MuLVand
a typical polytropic env sequence (Genebank accession
#33667793). As previously reported (Alamgir et al., 2005),
M-MuLV and polytropic env genes have a region of homology
(1033 nt), in the C-terminus of SU and most of TM; the overall
homology is 81% (Fig. 4A). The sequence alignments between
M-MuLV and SRS MuLV env genes with polytropic MuLV arewere assayed for the levels of MCF recombinants in bone marrow, spleen and
h organ were co-cultured with NIH-3T3 cell monolayers, and 3 days later, foci of
fic monoclonal antibody (514). The number of MCF-infected cells per 106 cells
animals showed noMCFs at early times: 4/4 at 12 days, 3/3 at 15 days and 3/3 at
rrow or spleen as well, althoughMCFs were detected in all thymuses. In parallel,
panels) by focal immunofluorescence assays with the MAb 548 that recognizes
Fig. 4. Sequence homology between polytropic, SRS and M-MuLV env genes. (A) A diagram of the regions of sequence homology between endogenous polytropic
MuLV env and SRS and M-MuLV is shown. (B) Sequence alignments in the region of sequence homology are shown; note the region of extremely high sequence
homology at the 5′ end.
12 S. Jahid et al. / Virology 351 (2006) 7–17shown for the regions of homology in Fig. 4B. As previously
noted (Alamgir et al., 2005), alignments between M-MuLVand
polytropic env in the homology region showed a 5′ region of
even higher homology (268 nt, 95% homology). The SRS
MuLV and polytropic envs show a similar region of extremely
high homology as for M-MuLV. Alamgir et al. have shown that
the high region of homology is the most common region for
cross-overs between M-MuLV and polytropic env sequences in
generation of M-MCF recombinants (Alamgir et al., 2005).Thus, the more rapid generation of MCF recombinants in SEM-
infected mice could not be attributed to higher homology
between the SEM and polytropic env genes.
To further analyze the MCF recombinants arising in SEM-
infected animals, sequence analysis was carried out. Tumor
DNAs from SEM-infected animals were subjected to PCR
amplification with two sets of primers that would amplify MCF
proviruses. The first set consisted of a forward primer from the
N-terminal region of the polytropic SU protein that would
Fig. 5. Organization of an SEMMCF. The general organization of an SEMMCF
is shown in the bottom figure. The polytropic MuLV-derived sequences are
shown in the hatched box. The locations of forward and reverse PCR primers for
amplification of MCF sequences are indicated by the arrows.
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sequences and a reverse primer from the U3 region of the M-
MuLV LTR (Fig. 5). Direct sequencing of the PCR products
from different tumors was carried out, and alignments between
SRS and endogenous MuLV env genes were performed. These
analyses indicated that the 3′ cross-over points were generally
near the region of extremely high homology. Therefore, a
second set of PCR amplifications with a forward polytropic
primer immediately upstream of the homology region and the
same reverse M-MuLV U3 primer was carried out. The
sequences facilitated identification of the cross-over points
(see below). In total, MCF env regions from 11 different tumors
were amplified and sequenced.
Recently, Alamgir et al. (2005) reported a comprehensive
analysis of MCF recombinants from M-MuLV-infected NFS/N
mice (inbred relatives of NIH Swiss mice). They had previously
cloned and sequenced almost all of the polytropic MuLV
proviruses in the NFS/N genome (Evans et al., 2003); this
allowed them to identify the particular endogenous polytropic
MuLV (or group of closely related proviruses) that participated
in formation of each M-MuLV MCF recombinant studied
(Alamgir et al., 2005). These studies greatly facilitated our
analysis of the SEM MCF recombinants. BLAST searches of
the mouse genome with each of the SEM MCF polytropic env
sequences were used to search for individual polytropic
proviruses or groups of related proviruses that participated in
formation of the MCF recombinant. Sequences obtained from
the upstream MCF primer were generally more informative
since they contained greater stretches of polytropic-derived
sequence. Depending on the length of the sequence obtainedTable 3
Endogenous polytropic proviruses participating in generation of SEM MCF recomb
Tumor Endogenous polytropic provirus
NC1 NC2 NC3 ND1 NE1 NF1 NG1 NH1 NI1 NN1 NP1
7f +
13f +? +? +?
15f +
1f +? +? +?
2f +? +? +? +?
5f +? +? +?
10f +? +?
3f +
a Env regions from MCF recombinants present in tumors from different animals w
polytropic proviruses present in the genome of NFS/N mice were performed, and pro
some cases, the donor could have been more than one polytropic provirus (+?). Polytr
mice (Alamgir et al., 2005) are underlined; those that are frequently used are underland on the particular MCF sequence, it was possible to assign
the polytropic provirus donor to one or a small number of
polytropic proviruses for 8 tumors, as shown in Table 3. A
variety of endogenous polytropic proviruses participated in
generation of SEM MCF recombinants that were also used in
formation of M-MuLV MCF recombinants (e.g. NC1/2/3 or
NQ1 [4 tumors] or NP1 [1 tumor]). Others (3/8) were used by
SEM but not found to be used by M-MuLV (ND1, NE1 and/or
NH1). Likewise, some polytropic proviruses used in generation
of M-MuLVMCFs were not found to participate in formation of
SEM MCFs, most notably NB1 that is commonly used by M-
MuLV (Alamgir et al., 2005). However, failure to detect NB1-
derived SEM MCFs may have been due to the somewhat
limited number of recombinants analyzed. Overall, it appeared
that an overlapping but distinct set of endogenous polytropic
proviruses was used to generate SEM MCF recombinants
compared to M-MuLV MCFs.
Comparison of the sequences of SEM MCF env genes with
the parental SRS MuLV and polytropic MuLVs allowed
mapping of the cross-over points for four recombinants (Fig.
6). The cross-overs were clustered ca. 90–120 nt downstream
from the region of extremely high homology. As mentioned
above, Alamgir et al. mapped the cross-over points for M-
MuLV MCFs within the region of extremely high homology
(Alamgir et al., 2005). Thus, the mechanisms of MCF
generation differed for M-MuLV and SEM.
Duplication of a subset of SRS enhancers results in enhanced
leukemogenicity and T-lymphoid disease
We previously studied a chimeric M-MuLV in which the
M-MuLV enhancers were replaced by the SRS MuLV enhan-
cers, ΔMo+SRS MuLV (Granger et al., 1999). This chimera
induced exclusively T-lymphomas, with a moderately increased
latency—contrary to our expectation of tumors of multiple
hematopoietic lineages. Analysis of the LTRs in the tumors
indicated that there had been tandemization of a subregion of
the SRS enhancers, encompassing adjacent binding sites for
Core and LvB (ets-1) factors. This suggested that these adjacent
sites might confer T-lymphoid specificity to the LTR, whileinants a
NQ1 NS1 NA1 NA2 NK1 NL1 NM1 NR1 NB1 NJ1 NO1
+?
+?
+?
+?
ere PCR-amplified and sequenced. Alignments with the different endogenous
viruses with 100% homology to the MCF env sequences were identified (+). In
opic proviruses used in the generation of Moloney MCF recombinants in NFS/N
ined and in bold.
Fig. 6. Cross-over points for SEMMCFs. MCF regions from SEM-induced tumors were PCR-amplified and sequenced. Sequence comparisons between the MCF env
sequences and the parental SRS and endogenous polytropic env sequences allowed identification of the cross-over points for four tumors. These points are indicated by
the underlined sequences; the length of the underlines indicates the region of uncertainty wherein cross-over took place. MCFs from two independent tumors contained
cross-over points in the same minimal region (1472–1477).
Fig. 7. Leukemogenicity of Scl-15. Leukemogenicity of Scl-15 is shown, com-
pared to wild-type andΔMo+SRS+M-MuLV. Data for wild-type andΔMo+SRS+
M-MuLVare from previous publications (Granger et al., 1999; Lander et al., 1999).
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other lineages. To test this, we cloned the enhancer sequences
from an LTR containing the tandemized Core/LvB sites from a
ΔMo+SRS MuLV-induced T-lymphoma back into the LTR of
M-MuLV, yielding Scl-15 M-MuLV. When this virus was
inoculated into neonatal NIH Swiss mice, all animals developed
T-lymphoma (12/14 exclusively T-lymphoma), as hypothesized
(Table 1). Moreover, the rate of disease development was
substantially increased (80d) in comparison to ΔMo+SRS+ M-
MuLV (140d; Granger et al., 1999), and even in comparison to
wild-type M-MuLV (110d, Fig. 7). This confirmed that the
subregion of the SRS enhancer containing the core/LvB sites
confers T-lymphoid specificity to the LTR and that duplication
of this sequence increases the rate of leukemogenicity.
Discussion
In these experiments, we investigated pathogenic determi-
nants of SRS MuLV by studying chimeras between this virus
and M-MuLV. Based on studies of other MuLV chimeras, we
expected to find that the SRS LTR would contain the major
determinant for multiple lineage leukemias associated with this
virus. An interesting aspect of the work was the non-reciprocal
behavior of reciprocal chimeras. When the M-MuLV LTR (U3
sequences) was substituted into SRS MuLV, the resulting
chimera (MLTR) induced exclusively lymphomas (predomi-
nantly T-lymphoma), indicating that the M-MuLV LTR carries a
strong determinant for T-lymphoid disease as predicted. On the
other hand, substitution of the SRS LTR (SLTR) into M-MuLV
yielded a chimera that still predominantly induced lymphomaand relatively little myeloid/erythroid leukemia. This indicated
that the SRS LTR by itself is not sufficient to fully shift the
pathogenic spectrum to that of SRS MuLV in the context of M-
MuLV. Thus, either M-MuLV carries an additional determinant
for T-lymphoma or SRS MuLV carries an additional determi-
nant for myeloid/erythroid leukemia. Indeed, the MES chimera,
in which both the LTR and gag–pol regions are derived from
SRS MuLV, was consistent with these possibilities—it induced
a high frequency of myeloid/erythroid leukemias. The recipro-
cal chimeras 5M3S and 5S3M that exchanged the gag–pol
regions were informative in this regard. 5M3S, which contains
M-MuLV gag–pol in SRS MuLV, induced mostly T-lymphoma
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indeed a determinant for T-lymphoma in the M-MuLV gag–pol
region. On the other hand, 5S3M did not show substantial rates
of myeloid/erythroid leukemia, which indicates that SRS MuLV
does not have an equivalent determinant for myeloid/erythroid
leukemia in gag–pol, or that it is not capable of counteracting
the T-lymphoid nature of the M-MuLV LTR.
The nature of the T-lymphoid determinant in theM-MuLV gag–
pol region remains to be determined. This could reflect a tissue-
specific transcriptional enhancer sequence in this region of the M-
MuLV genome. Alternatively, it might reflect other mechanisms.
For instance, the presence of a splicing enhancer in the gag region
of a recombinant avian EU8 retrovirus has been associated with its
ability to induce rapid B-lymphomas in neonatally infected
chickens; this element is important for activation of the c-myb
oncogene by promoter insertion and splicing (Beemon et al., 1997).
Audit et al. (1999) also reported the existence of a highly conserved
alternative splice donor site in the gag region ofM-MuLV;mutation
of this site shifted the disease spectrum from T-lymphoma to
multiple lineages remarkably similar to that of SRS MuLV.
However, SRS retains the conserved alternative splice donor site,
although the surrounding sequences differ. Holland et al. have also
reported a determinant in gag that influences the rate at which the
pathogenic AKR MuLV-derived MCF 247 induces T-lymphoma,
although in this case the disease spectrum was not shifted (Holland
et al., 1985). In the future, it will be interesting to refine the location
of T-lymphoid determinant in M-MuLV gag–pol, which will
facilitate studies on the mechanism of action.
The experiments also indicated that chimeras with the SRS
MuLVLTRgenerally induced tumors less rapidly than those driven
by the M-MuLV LTR. This was consistent with the notion that the
SRS MuLV LTR may be weaker as a promoter/enhancer in
lymphoid cells than the M-MuLV LTR. It should be noted that the
SRSMuLVLTR does not contain a tandem repeat in the U3 region
(Bundy et al., 1995), while the M-MuLV LTR does (Linney et al.,
1984), which would be consistent with SRS MuLV's slower
disease induction.We previously described studies onΔMo+SRS+
M-MuLV, a virus driven by the SRSMuLVU3 enhancer sequences
(Granger et al., 1999). The results with this virus are consistent with
these results. First, the slower rate of disease is consistent with the
JSRV enhancers being less potent than the M-MuLV enhancers.
Second, the fact that this virus induces T-lymphoma is consistent
with the presence of a T-lymphoid determinant in the M-MuLV
gag–pol region. Finally, as shown in this study, a ΔMo+SRS LTR
in which a portion of the SRS enhancers was duplicated (Sc-15 M-
MuLV) showed greatly accelerated development of T-lymphoma
(indeed to more rapid than wild-type M-MuLV).
The other noteworthy aspect of these studies was that
substitution of the SRS env region into M-MuLV (SEM)
accelerated development of disease, while substitution of M-
MuLVenv into SRS MuLV retarded it. The acceleration of disease
by SEM was studied in detail. An interesting correlation was
observed with the more rapid appearance of MCF recombinants in
the infected animals. This did not simply reflect more efficient
infection with the input virus, but rather a more rapid generation of
MCFs. This result supports both the importance of MCF
recombinants for MuLV leukemogenesis and also a role forMCFs early in the development of disease (Brightman et al., 1991;
Li and Fan, 1991).
The reason that SEM generates MCF recombinants more
rapidly than M-MuLV is unclear and will require additional
experimentation. It could not be attributed to higher homology
between polytropic and SEM env sequences. MCF recombinant
formation showed some mechanistic differences between SEM
and M-MuLV. First, an overlapping but distinct set of
endogenous polytropic proviruses participated in MCF forma-
tion. (In the case of the NB1 endogenous provirus that is used
by M-MuLV but not detected in SEM MCFs, it is formally
possible that the random-bred NIH Swiss mice do not contain
this provirus, even though the NFS/N mice do.) Second, while
the M-MuLV MCF cross-over points were typically located in
the region of extremely high homology (Alamgir et al., 2005),
the SEM MCF cross-overs occurred 90–120 nt downstream in
the region of moderately high homology. The cross-over
regions for MCFs derived from AKR and Friend MuLVs are
also further down from the region of extremely high homology
(Evans, 1986; Evans and Cloyd, 1985), although SRS env is
evolutionarily most closely related to M-MuLV (Bundy and
Fan, 1999). One possible explanation for the different
mechanism of MCF formation could be that the SRS M-
MuLV Env protein might have somewhat different entry
properties than M-MuLV Env, although both viruses are
ecotropic (Bundy et al., 1995) (using the mCAT-1 amino acid
transporter as receptor (Kim et al., 1991)). If SRS Env has
higher affinity for mCAT-1, this might allow it to infect cells
with low densities of mCAT-1 that may not be as readily
infected by M-MuLV. Infection of novel cells could result in a
more rapid generation of MCFs if those cells express higher
levels and/or different spectra of endogenous polytropic
MuLVs, or if they support higher frequencies of recombination.
Another possibility could be that SRS Env interacts with a co-
receptor molecule or attachment factor that might facilitate
infection in cell types that are not infected by M-MuLV.
Two other properties of these chimeras deserve comment. First,
substitution of the M-MuLV env into SRS MuLV further retarded
the rate of leukemogenicity. One possible explanation could be that
this virus forms MCF recombinants more slowly than the same
virus containing SRS env—that is, SRS Env facilitates MCF
formation more efficiently than does M-MuLV env. Second,
substitution of the SRS Env into M-MuLV (SEM) somewhat
shifted the resulting tumors from 100% T-lymphoid (Brightman et
al., 1988) to both B- and T-lymphoid. One possible explanation
could be that SRS Env facilitates infection of B-lymphoid cells
more efficiently than M-MuLV Env by one of the mechanisms
discussed in the preceding paragraph. It will be interesting to
explore these possibilities in future experiments.
Materials and methods
Generation of chimeric viruses
Chimeric virus clones were generated starting with
molecular clones of proviruses for SRS 19-6 MuLV (p19-6
MuLV) and M-MuLV (p63-2) as previously described (Bundy
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provided upon request. Common restriction sites used were
the HindIII site at the 3′ end of pol (nt 4881) and the NheI
site at the 5′ end of the LTR (nt 7846). pSLTR (SRS LTR in
M-MuLV) resulted from exchange of the downstream SRS
LTR into the M-MuLV plasmid p63-2 at the NheI site, and
the reciprocal recombinant pMLTR was generated similarly.
pSEM (SRS env in M-MuLV) resulted from exchange of the
SRS env region (between the HindIII and NheI sites) into
p63-2, and the reciprocal plasmid pMES was generated
similarly. p5S3M was a plasmid consisting of pSRS 19-6
MuLV to the 5′ side of the HindIII site, and p63-2 to the 3′
side (5′ SRS, 3′ M-MuLV), and p5M3S was generated in a
similar manner. Scl-15 was a derivative of the M-MuLV p63-
2 proviral plasmid. We had previously described generation of
ΔMo+SRS+ M-MuLV, in which M-MuLV is driven by the
SRS 19-6 MuLV enhancer sequences (Granger et al., 1999).
T-lymphoid tumors resulting from this virus showed tandem
duplication or higher multimerization of a subregion of the
SRS enhancers. The LTR from one of these tumors contain-
ing a duplication of the Core/Lv-b motifs was cloned and
introduced back into p63-2 to give pScl-15 M-MuLV.
Infectious MuLVs were obtained by transfection of each of
the chimeric plasmids into NIH-3T3 cells as described
previously (Overhauser and Fan, 1985). The transfected
cultures were transferred serially 3–4 times, until they were
confluently infected as determined by XC cell overlays and
observation for syncytia formation (Rowe et al., 1970). The
organizations of the resulting chimeric viruses in proviral form
(lacking the plasmid prefix—SLTR vs. pSLTR) are shown in
Fig. 1. Note that chimeric plasmids with alterations in the U3
region of the downstream LTR (e.g. pSLTR) give rise to
recombinant proviruses with alterations in both LTRs. Tissue
culture supernatants from the transfected cells were passed
through 0.2 μ filters, divided into aliquots and stored at −80 °C
as viral stocks. Viral stocks were titered by focal infectivity
assays with monoclonal antibodies as described previously
(Lander et al., 1999).
In vivo inoculations
Neonatal NIH Swiss mice were inoculated intraperitoneally
(IP) with 0.2 ml viral stock (5 × 105 to 1 × 106 IU/ml) as
described previously (Davis et al., 1985). The animals were
observed until they showed signs of disease, at which point they
were sacrificed and subjected to necropsy (Bundy et al., 1995).
Hematocrits were measured, and blood smears and touch prints
of spleen, liver and other enlarged organs were prepared.
Portions of tumor tissues were also frozen and fixed in
formaldehyde for further analysis.
Tumor diagnosis
Tumor diagnosis employed a combination of criteria.
Cellular DNAs from enlarged organs were analyzed for
rearrangements of the T-cell receptor beta (TCR-beta), immu-
noglobulin mu heavy chain (IgM) and kappa light chain (IgK)genes by restriction endonuclease digestion and Southern blot
hybridization as described previously (Brightman et al., 1988).
Tumor tissues showing gene rearrangements for TCR-beta were
classified as containing T-lymphoma, while those containing
IgK gene rearrangements were classified as containing B-
lymphoma. Tumors that showed IgM rearrangements (but no
TCR-beta rearrangements) were classified as containing B-
lymphoma or pre-B-lymphoma, depending on whether the IgK
gene showed rearrangement as well. Animals showing below
normal hematocrits (<29% for females, <31% for males) were
classified as having myeloid and/or erythroid leukemia. For a
subset of tumors where diagnoses were not definitive (e.g.
borderline hematocrits), histopathology of blood smears or
tumor touch prints was also performed.
MCF recombinant analysis
The appearance of MCF recombinants in SEM or M-
MuLV-infected animals was detected by measuring the
number of MCF infectious centers at different days of age,
by co-culturing bone marrow, spleen and thymus cells with
NIH-3T3 cell monolayers and observing local regions of
infection by focal immunofluorescence with MAb 514 (that
recognizes most MCFs) as described previously (Lander et
al., 1999). In parallel, the appearance of ecotropic MuLV was
measured by infectious center/FIA assay with MAb 548 that
is reactive against M-MuLV glycosylated gag (that is encoded
by both SEM and M-MuLV).
Molecular characterization of the MCFs in SEM-induced
tumors employed PCR amplification of MCF env regions from
tumors. Forward primers were from conserved polytropic env
sequences from near the 5′ receptor-binding domain (primer
MX33, ATGACAGGACAAACAGCTAATGCT; Stoye and
Coffin, 1987) or from the region immediately upstream of
the homology region between polytropic and SRS envs
(ATCACTGACCAGTTACCCCCC). The reverse primer was
from the U3 region of the M-MuLV LTR (primer 2a,
GGGGCACCCTGGAAACATCTGATGGT; Granger and
Fan, 1998). PCR amplification of tumor DNAs was performed
with these primers, and the PCR products were directly
sequenced by chain termination sequencing using the same
forward primers and analyzed in the UCI Cancer Center DNA
Sequencing shared resource. Alignments of the polytropic-
specific regions in the MCFs from each tumor against the
mouse genome sequence were performed with the BLAST
program to search for the most likely endogenous polytropic
MuLV donor(s). Cross-reference to the designations for the
polytropic env genes from NFS/N mice by Alamgir et al.
(2005) was also carried out.
Acknowledgments
This work was supported NIH grant R01 CA32455 to HF.
The excellent technical assistance of Vaishali Kulkarni, Huong
Vu and Mina Park is acknowledged. Support of the UCI Cancer
Center DNA Sequencing Shared Resource is also appreciated.
We thank Jonathan Stoye and Leonard Evans for advice.
17S. Jahid et al. / Virology 351 (2006) 7–17References
Alamgir, A.S., Owens, N., Lavignon, M., Malik, F., Evans, L.H., 2005. Precise
identification of endogenous proviruses of NFS/N mice participating in
recombination with moloney ecotropic murine leukemia virus (MuLV) to
generate polytropic MuLVs. J. Virol. 79 (8), 4664–4671.
Audit, M., Dejardin, J., Hohl, B., Sidobre, C., Hope, T.J., Mougel, M.,
Sitbon, M., 1999. Introduction of a cis-acting mutation in the capsid-
coding gene of moloney murine leukemia virus extends its leukemogenic
properties. J. Virol. 73 (12), 10472–10479.
Bear, S.E., Bellacosa, A., Lazo, P.A., Jenkins, N.A., Copeland, N.G.,
Hanson, C., Levan, G., Tsichlis, P.N., 1989. Provirus insertion in Tpl-1,
an Ets-1-related oncogene, is associated with tumor progression in
Moloney murine leukemia virus-induced rat thymic lymphomas. Proc.
Natl. Acad. Sci. U.S.A. 86 (19), 7495–7499.
Beemon, K.L., O'Reilly, M.M., Smith, M.R., Smith, R.E., Dunkel, I., Hayward,
W.S., 1997. Rapid induction of B-cell lymphomas by avian leukosis virus.
Leukemia 11 (Suppl. 3), 179–182.
Bonzon, C., Fan, H., 2000. Moloney murine leukemia virus-induced tumors
show altered levels of proapoptotic and antiapoptotic proteins. J. Virol. 74
(17), 8151–8158.
Brightman, B.K., Chandy, K.G., Spencer, R.H., Gupta, S., Pattengale, P.K., Fan,
H., 1988. Characterization of lymphoid tumors induced by a recombinant
murine retrovirus carrying the avian v-myc oncogene. Identification of novel
(B-lymphoid) tumors in the thymus. J. Immunol. 141 (8), 2844–2854.
Brightman, B.K., Rein, A., Trepp, D.J., Fan, H., 1991. An enhancer variant of
Moloney murine leukemia virus defective in leukemogenesis does not
generate detectable mink cell focus-inducing virus in vivo. Proc. Natl. Acad.
Sci. U.S.A. 88 (6), 2264–2268.
Bundy, L.M., Fan, H., 1999. Molecular and phylogenetic analysis of SRS 19-6
murine leukemia virus. Virus Genes 18 (1), 65–79.
Bundy, L.M., Ru, M., Zheng, B.F., Cheng, L., Pattengale, P.K., Portis, J.L., Fan,
H., 1995. Biological characterization and molecular cloning of murine C-
type retroviruses derived from the TSZ complex from mainland China.
Virology 212 (2), 367–382.
Chatis, P.A., Holland, C.A., Silver, J.E., Frederickson, T.N., Hopkins, N.,
Hartley, J.W., 1984. A 3′ end fragment encompassing the transcriptional
enhancers of nondefective Friend virus confers erythroleukemogenicity on
Moloney leukemia virus. J. Virol. 52 (1), 248–254.
Chesebro, B., Wehrly, K., Cloyd, M., Britt, W., Portis, J., Collins, J., Nishio, J.,
1981. Characterization of mouse monoclonal antibodies specific for Friend
murine leukemia virus-induced erythroleukemia cells: friend-specific and
FMR-specific antigens. Virology 112 (1), 131–144.
Cloyd, M.W., Evans, L.H., 1987. Endogenous retroviral env expression in
primary murine leukemias: lack of xenotropic antigens but presence of
distinct mink cell focus-forming env subtypes correlating with ecotropic
virus inoculated and mouse strain. J. Natl. Cancer Inst. 78 (1), 181–189.
Cuypers, H.T., Selten, G., Quint, W., Zijlstra, M., Maandag, E.R., Boelens, W.,
van Wezenbeek, P., Melief, C., Berns, A., 1984. Murine leukemia virus-
induced T-cell lymphomagenesis: integration of proviruses in a distinct
chromosomal region. Cell 37 (1), 141–150.
Davis, B., Linney, E., Fan, H., 1985. Suppression of leukaemia virus
pathogenicity by polyoma virus enhancers. Nature 314 (6011), 550–553.
Evans, L.H., 1986. Characterization of polytropic MuLVs from three-week-old
AKR/J mice. Virology 153 (1), 122–136.
Evans, L.H., Cloyd, M.W., 1985. Friend and Moloney murine leukemia viruses
specifically recombine with different endogenous retroviral sequences to
generate mink cell focus-forming viruses. Proc. Natl. Acad. Sci. U.S.A. 82
(2), 459–463.
Evans, L.H., Lavignon, M., Taylor, M., Alamgir, A.S., 2003. Antigenic
subclasses of polytropic murine leukemia virus (MLV) isolates reflect three
distinct groups of endogenous polytropic MLV-related sequences in NFS/N
mice. J. Virol. 77 (19), 10327–10338.
Fan, H., 1997. Leukemogenesis by Moloney murine leukemia virus: a multistep
process. Trends Microbiol. 5 (2), 74–82.Frankel, W.N., Stoye, J.P., Taylor, B.A., Coffin, J.M., 1989. Genetic
identification of endogenous polytropic proviruses by using recombinant
inbred mice. J. Virol. 63 (9), 3810–3821.
Granger, S.W., Fan, H., 1998. In vivo footprinting of the enhancer sequences in
the upstream long terminal repeat of Moloney murine leukemia virus:
differential binding of nuclear factors in different cell types. J. Virol. 72 (11),
8961–8970.
Granger, S.W., Bundy, L.M., Fan, H., 1999. Tandemization of a subregion of the
enhancer sequences from SRS 19-6 murine leukemia virus associated with
T-lymphoid but not other leukemias. J. Virol. 73 (9), 7175–7184.
Hartley, J.W., Wolford, N.K., Old, L.J., Rowe, W.P., 1977. A new class of
murine leukemia virus associated with development of spontaneous
lymphomas. Proc. Natl. Acad. Sci. U.S.A. 74 (2), 789–792.
Holland, C.A., Hartley, J.W., Rowe, W.P., Hopkins, N., 1985. At least four viral
genes contribute to the leukemogenicity of murine retrovirus MCF 247 in
AKR mice. J. Virol. 53 (1), 158–165.
Kim, J.W., Closs, E.I., Albritton, L.M., Cunningham, J.M., 1991. Transport of
cationic amino acids by the mouse ecotropic retrovirus receptor. Nature 352
(6337), 725–728.
Lander, J.K., Chesebro, B., Fan, H., 1999. Appearance of mink cell focus-
inducing recombinants during in vivo infection by moloney murine
leukemia virus (M-MuLV) or the Mo+PyF101 M-MuLV enhancer variant:
implications for sites of generation and roles in leukemogenesis. J. Virol. 73
(7), 5671–5680.
Li, Q.X., Fan, H., 1990. Combined infection by Moloney murine leukemia virus
and a mink cell focus-forming virus recombinant induces cytopathic effects
in fibroblasts or in long-term bone marrow cultures from preleukemic mice.
J. Virol. 64 (8), 3701–3711.
Li, Q.X., Fan, H., 1991. Bone marrow depletion by 89Sr complements a
preleukemic defect in a long terminal repeat variant of Moloney murine
leukemia virus. J. Virol. 65 (8), 4442–4448.
Li, Y., Golemis, E., Hartley, J.W., Hopkins, N., 1987. Disease specificity of
nondefective Friend andMoloney murine leukemia viruses is controlled by a
small number of nucleotides. J. Virol. 61 (3), 693–700.
Linney, E., Davis, B., Overhauser, J., Chao, E., Fan, H., 1984. Non-function of a
Moloney murine leukaemia virus regulatory sequence in F9 embryonal
carcinoma cells. Nature 308 (5958), 470–472.
Nusse, R., Varmus, H.E., 1982. Many tumors induced by the mouse mammary
tumor virus contain a provirus integrated in the same region of the host
genome. Cell 31 (1), 99–109.
Overhauser, J., Fan, H., 1985. Generation of glucocorticoid-responsive Moloney
murine leukemia virus by insertion of regulatory sequences from murine
mammary tumor virus into the long terminal repeat. J. Virol. 54 (1),
133–144.
Patriotis, C., Makris, A., Bear, S.E., Tsichlis, P.N., 1993. Tumor progression
locus 2 (Tpl-2) encodes a protein kinase involved in the progression of
rodent T-cell lymphomas and in T-cell activation. Proc. Natl. Acad. Sci.
U.S.A. 90 (6), 2251–2255.
Rosenberg, N., Jolicoeur, P., 1997. Retroviral pathogenesis. In: Coffin, J.,
Hughes, S.H., Varmus, H.E. (Eds.), Retroviruses. Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, NY, pp. 475–585.
Rowe, W.P., Pugh, W.E., Hartley, J.W., 1970. Plaque assay techniques for
murine leukemia viruses. Virology 42 (4), 1136–1139.
Stoye, J.P., Coffin, J.M., 1987. The four classes of endogenous murine leukemia
virus: structural relationships and potential for recombination. J. Virol. 61
(9), 2659–2669.
Stoye, J.P., Moroni, C., Coffin, J.M., 1991. Virological events leading to
spontaneous AKR thymomas. J. Virol. 65 (3), 1273–1285.
Suzuki, T., Shen, H., Akagi, K., Morse, H.C., Malley, J.D., Naiman, D.Q.,
Jenkins, N.A., Copeland, N.G., 2002. New genes involved in cancer
identified by retroviral tagging. Nat. Genet. 32 (1), 166–174.
Telesnitsky, A., Goff, S.P., 1997. Reverse transcriptase and the generation of
retroviral DNA. In: Coffin, J.M., Hughes, S.H., Varmus, H.E. (Eds.),
Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
NY, pp. 121–160.
